Azilsartan Medoxomil – 1 mg

Brand:
Cayman
CAS:
863031-21-4
Storage:
-20
UN-No:
Non-Hazardous - /

Azilsartan medoxomil is a prodrug form of azilsartan (Item No. 26091), a potent and selective angiotensin II receptor 1 (AT1) antagonist.{36288,36289} Azilsartan medoxomil (0.1-10 mg/kg) reduces blood pressure and decreases plasminogen activator inhibitor 1 (PAI-1) levels in the plasma, left ventricle, and aortic wall in mice in a dose-dependent manner.{36289} It also inhibits the pressor response induced by angiotensin II (Item No. 17150) in normotensive rats (ID50 = 0.12 mg/kg) and reduces blood pressure and improves glucose infusion, a marker of insulin sensitivity, in spontaneously hypertensive rats.{36290} Azilsartan medoxomil also has more potent antiproteinuric effects in Wistar fatty rats than olmesartan medoxomil (Item No. 11614). Formulations containing azilsartan medoxomil have been used in the treatment of hypertension.  

 

Available on backorder

SKU: 23805 - 1 mg Category:

Description

A prodrug form of azilsartan; reduces blood pressure and decreases PAI-1 levels in the plasma, left ventricle, and aortic wall in mice in a dose-dependent manner when administered at doses ranging from 0.1-10 mg/kg; inhibits the angiotensin II-induced pressor response in normotensive rats (ID50 = 0.12 mg/kg); reduces blood pressure and improves glucose infusion in spontaneously hypertensive rats; has more potent antiproteinuric effects in Wistar fatty rats than olmesartan medoxomil


Formal name: 1-[[2′-(2,5-dihydro-5-oxo-1,2,4-oxadiazol-3-yl)[1,1′-biphenyl]-4-yl]methyl]-2-ethoxy-1H-benzimidazole-7-carboxylic acid, (5-methyl-2-oxo-1,3-dioxol-4-yl)methyl ester

Synonyms:  TAK-491

Molecular weight: 568.5

CAS: 863031-21-4

Purity: ≥98%

Formulation: A solid


Product Type|Biochemicals|Receptor Pharmacology|Antagonists||Research Area|Cardiovascular System|Blood|Serum Proteins||Research Area|Cardiovascular System|Cardiovascular Diseases|Hypertension||Research Area|Cardiovascular System|Kidney & Renal Disease||Research Area|Cardiovascular System|Vasculature|Vasodilation||Research Area|Endocrinology & Metabolism|Metabolic Diseases|Diabetes